A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS

被引：0

作者：

Puduvalli, Vinay ^{[1
]}

Wu, Jing ^{[2
]}

Yuan, Ying ^{[3
]}

Armstrong, Terri ^{[2
]}

Wu, Jimin ^{[3
]}

Giglio, Pierre ^{[4
]}

Xu, Jihong ^{[1
]}

Colman, Howard ^{[5
,6
]}

Walbert, Tobias ^{[7
]}

Raizer, Jeffrey ^{[8
]}

Groves, Morris ^{[9
]}

Iwamoto, Fabio ^{[10
]}

Tran, David ^{[11
]}

Avgeropoulos, Nicholas ^{[12
]}

Paleologos, Nina ^{[13
]}

Fink, Karen ^{[14
]}

Peereboom, David ^{[15
]}

Chamberlain, Marc ^{[16
]}

Merrell, Ryan ^{[17
]}

Penas-Prado, Marta ^{[3
]}

Yung, W. K. Alfred ^{[18
]}

Gilbert, Mark ^{[2
]}

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[2] NCI, Neurooncol Branch, CCR, NIH, Bethesda, MD 20892 USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Ohio State Univ, Columbus, OH 43210 USA

[5] Univ Utah, Dept Neurosurg, Huntsman Canc Inst, Salt Lake City, UT USA

[6] Univ Utah, Clin Neurosci Ctr, Salt Lake City, UT USA

[7] Henry Ford Hosp, Detroit, MI 48202 USA

[8] Northwestern Univ, Chicago, IL 60611 USA

[9] Texas Oncol Austin Brain Tumor Ctr, Austin, TX USA

[10] Columbia Univ, New York, NY USA

[11] Univ Florida, Gainesville, FL USA

[12] Univ Florida, Orlando, FL USA

[13] Advocate Hlth Care, Chicago, IL USA

[14] Baylor Univ, Dallas, TX USA

[15] Cleveland Clin, Cleveland, OH 44106 USA

[16] Univ Washington, Seattle, WA 98195 USA

[17] Northshore Univ, Evanston, IL USA

[18] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA

来源：

NEURO-ONCOLOGY | 2018年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ACTR-13

引用

页码：13 / 13

页数：1

共 50 条

[21] NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance).
Galanis, Evanthia
Anderson, S. Keith
Butowski, Nicholas A.
Hormigo, Adilia
Schiff, David
Tran, David Dinh
Omuro, Antonio Marcilio Padula
Jaeckle, Kurt A.
Kumar, Shaji
Kaufmann, Timothy J.
Buckner, Jan C.
Twohy, Erin
Giannini, Caterina
Wen, Patrick Y.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[22] PHASE II TRIAL OF ENZASTAURIN (ENZ) WITH BEVACIZUMAB (BV) IN ADULTS WITH RECURRENT GLIOBLASTOMA (GEM)
Moustakas, Argirios
Iwamoto, Fabio M.
Kreisl, Teri N.
Sul, Joohee
Kim, Lyndon
Butman, John
Albert, Paul
Fine, Howard A.
NEURO-ONCOLOGY, 2010, 12 : 37 - 37
[23] NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Tsien, Christina I.
Pugh, Stephanie L.
Dicker, Adam P.
Raizer, Jeffrey J.
Matuszak, Martha M.
Lallana, Enrico C.
Huang, Jiayi
Algan, Ozer
Deb, Nimisha
Portelance, Lorraine
Villano, John L.
Hamm, John T.
Oh, Kevin S.
Ali, Arif N.
Kim, Michelle M.
Lindhorst, Scott M.
Mehta, Minesh P.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1285 - +
[24] Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)
Galanis, Evanthia
Anderson, S. Keith
Twohy, Erin
Butowski, Nicholas A.
Hormigo, Adilia
Schiff, David
Omuro, Antonio
Jaeckle, Kurt A.
Kumar, Shaji
Kaufmann, Timothy J.
Geyer, Susan
Kumthekar, Priya U.
Campian, Jian
Giannini, Caterina
Buckner, Jan C.
Wen, Patrick Y.
NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
[25] A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Arrillaga-Romany, Isabel
Sahebjam, Solmaz
Picconi, David
Campian, Jian
Giglio, Pierre
Drappatz, Jan
Aiken, Robert
Villano, John
Lee, Eudocia
Welch, Mary
Ellingson, Benjamin
Ney, Douglas
Becker, Kevin
Muzikansky, Alona
Das, Biswajit
Swisher, Elizabeth
Nixon, Andrew
Karlovich, Chris
Williams, P. Mickey
Ivy, S. Percy
Batchelor, Tracy
Gerstner, Elizabeth
NEURO-ONCOLOGY, 2019, 21 : 27 - 27
[26] A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE: PRELIMINARY RESULTS OF THE DUTCH BELOB STUDY
Taal, Walter
Walenkamp, Annemiek M.
Taphoorn, Martin J.
Beerepoot, Laurens
Hanse, Monique
Buter, Jan
Honkoop, Aafke
Groenewegen, Gerard
Boerman, Dolf
Jansen, Rob L.
van den Berkmortel, Franchette W.
Brandsma, Dieta
Kros, Johan M.
Bromberg, Jacoline E.
van Heuvel, Irene
Smits, Marion
van der Holt, B.
Vernhout, Rene
van den Bent, Martin
NEURO-ONCOLOGY, 2012, 14 : 57 - 58
[27] Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM)
Sathornsumetee, Sith
Vredenburgh, James
Rich, Jeremy
Desjardins, Annick
Quinn, Jennifer
Bota, Daniela
Goli, Krishna
Mathe, Alyssa
Gururangan, Sridharan
Friedman, Allan
Friedman, Henry
Reardon, David
NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
[28] RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA
Ahluwalia, Manmeet
Peereboom, David
Schilero, Cathy
Forst, Deborah
Wong, Eric
Wen, Patrick
Reardon, David
NEURO-ONCOLOGY, 2018, 20 : 234 - 234
[29] Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
Peters, Katherine B.
Lipp, Eric S.
Miller, Elizabeth
Herndon, James E., II
McSherry, Frances
Desjardins, Annick
Reardon, David A.
Friedman, Henry S.
JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (02) : 349 - 356
[30] Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
Katherine B. Peters
Eric S. Lipp
Elizabeth Miller
James E. Herndon
Frances McSherry
Annick Desjardins
David A. Reardon
Henry S. Friedman
Journal of Neuro-Oncology, 2018, 137 : 349 - 356

← 1 2 3 4 5 →